Intraperitoneal Stem Cell Therapy Reduces Intestinal and Lung Inflammation in Mouse Model of Necrotizing Enterocolitis

Researchers have developed an intraperitoneal stem cell therapy that significantly reduces inflammation associated with necrotizing enterocolitis (NEC) in a mouse model. The study demonstrates the treatment’s ability to mitigate severe intestinal injury, which is a defining characteristic of NEC, while also uncovering protective effects on lung tissue. NEC is a life-threatening condition primarily affecting premature infants, and this research highlights potential advancements in neonatal care.

The findings indicate that the stem cell therapy not only addresses intestinal damage but also provides unexpected benefits for pulmonary health. Researchers observed reduced inflammation in both the intestines and lungs following treatment, suggesting broader systemic effects of the therapy. The study utilized a murine model to simulate severe cases of NEC and evaluated the efficacy of administering stem cells directly into the peritoneal cavity. This approach marks a significant step forward in understanding how stem cell treatments could be applied to combat complex inflammatory conditions like NEC.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 2, 2025

Related posts:

Russian Pharmaceutical Industry Grows with Government Support, R-Pharm Partners with Pfizer and Sanofi Pharmaceutical Companies Prioritize Collaboration Between Marcomms and IT Teams to Advance Omnichannel Strategies Climate-Smart Farming Boosts Smallholder Incomes in Ethiopia’s Adami Tullu Jido Kombolcha District Nursing Brand Image Scale Adapted and Validated for German-Speaking Populations

Author

GOAI